AML Case: A 54-year-old woman is in remission but MRD+

AML Case: A 54-year-old woman is in remission but MRD+

imedex

5 months
114 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Earn CME: https://naccme.com/program/7331 In this presentation from the 'Looking to the Future With Hope: Advances in the Treatment of AML' symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Mojtaba Akhtari discusses a patient case to examine whether transplant, conventional therapy, or novel targeted is most appropriate for the MRD+ patient subset and in what conditions. © 2019 Imedex, an HMP Company
Up Next Autoplay
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Category: Acute Myelogenous Leukemia
14 Views
Cancer-News 3 weeks
How to Manage MDS Patients who are Ineligible for Transplant
How to Manage MDS Patients who are Ineligible for Transplant
Category: Acute Myelogenous Leukemia
298 Views
obr 4 months
The Recent Wave of Approval in AML
The Recent Wave of Approval in AML
Category: Acute Myelogenous Leukemia
137 Views
obr 4 months
Updated Data on Gilteritinib in AML
Updated Data on Gilteritinib in AML
Category: Acute Myelogenous Leukemia
15 Views
obr 4 months
Latest Data on Uproleselan with Chemotherapy
Latest Data on Uproleselan with Chemotherapy
Category: Acute Myelogenous Leukemia
98 Views
obr 4 months
Update: New Drugs for AML
Update: New Drugs for AML
Category: Acute Myelogenous Leukemia
175 Views
imedex 5 months
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Category: Acute Myelogenous Leukemia
100 Views
Annual-Meeting 5 months
Should We Check If The Donor Has A Mutation: Depends On The Type Of Mutation, Not Every Mutation Is The Same
Should We Check If The Donor Has A Mutation: Depends On The Type Of Mutation, Not Every Mutation Is The Same
Category: Acute Myelogenous Leukemia
107 Views
Annual-Meeting 5 months
Lenalidomide + Azacitidine Graft v Host
Lenalidomide + Azacitidine Graft v Host
Category: Acute Myelogenous Leukemia
61 Views
Annual-Meeting 5 months